Breakfast Brief with PD DDr. Sacha Rothschild
In this Breakfast Brief, PD DDr. Sacha Rothschild presents his Immuno-Oncology highlights of the first two days of ASCO Congress 2018
PD DDr. Sacha Rothschild presenting in his Breakfast Brief following abstracts:
Source: ASCO Annual Meeting 2018
- Abstract 6009:
A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).
https://meetinglibrary.asco.org/record/160233/abstract
Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).
Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).
Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.